Overview

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

Status:
Not yet recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation

Phase:

Phase 2

Details

Lead Sponsor:

Sheppard Pratt Health System

Collaborator:

COMPASS Pathways

Treatments:

Psilocybin